✦ LIBER ✦

Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer

✍ Scribed by P. Pfeiffer; J.P. Mortensen; B. Bjerregaard; L. Eckhoff; K. Schønnemann; E. Sandberg; K. Aabo; A. Jakobsen

Book ID: 116429105
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 155 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2006.06.027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient preference and pharmacokinetics

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

✍ M.M Borner; P Schöffski; R de Wit; F Caponigro; G Comella; A Sulkes; G Greim; G. 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 169 KB

A randomised cross-over trial comparing

A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil

✍ Wesely Shiu; Victor Tsang; Yuk M. Lam; Alex Zacharia; W. M. Craig Martin 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 326 KB

Randomised phase III trial of adjuvant c

Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205

✍ Shimada, Yasuhiro; Hamaguchi, Tetsuya; Mizusawa, Junki; Saito, Norio; Kanemitsu, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 582 KB

597 ORAL A randomised phase III multicen

597 ORAL A randomised phase III multicenter trial comparing irinotecan in combination with either the Nordic bolus 5FU and folinic acid (5FU/FA) schedule (FLIRI) or the bolus/infused de Gramont schedule (FOLFIRI), in patients with metastatic colorectal cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Imatinib mesylate for targeting the plat

Imatinib mesylate for targeting the platelet-derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer—A dose-escalation Phase I trial

✍ Salah-Eddin Al-Batran; Akin Atmaca; Eberhard Schleyer; Claudia Pauligk; Christia 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

## Abstract ## BACKGROUND. In previous experimental models, because of its ability to inhibit the activity of platelet‐derived growth factor β receptor, imatinib decreased the interstitial fluid pressure and improved the delivery and efficacy of anticancer drugs, including fluorouracil. The object